TKI resistance related genes in LUAD predict patient prognosis and tumor immune microenvironment with LHX2 as a hub gene

Abstract Background Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (LUAD), is a leading cause of cancer-related mortality. Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), improves survival, but acquired resistance remains a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Ruohan Huang, Qi Liang, Hongya Wang, Huizhu Qian, Renhua Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2025-11-01
coleção:	Discover Oncology
Assuntos:	NSCLC Osimertinib Drug resistance LHX2 Prognosis productive model
Acesso em linha:	https://doi.org/10.1007/s12672-025-03959-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!